Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced a $50 million growth financing. New investor Sectoral Asset Management joined lead investor Novo Holdings and returning investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group in the financing round.

Proceeds from the financing will support the next phase of Route 92 Medical’s growth strategy by helping to accelerate global commercial expansion, advance clinical evidence to support broader adoption of the company’s neurovascular procedural approach and invest in continued product innovation across its platform.

“We’ve seen rapid growth in the adoption of our products over the past year, attributable to the clinical performance of our Monopoint approach, and the growth and dedication of our commercial organization,” said Tony Chou, MD, Chief Executive Officer and Founder of Route 92 Medical. “We’re on a mission to improve outcomes for patients suffering from acute ischemic stroke and our rapidly growing sales are a testament to the differentiated, physician-preferred attributes of our neurovascular thrombectomy solutions.”

“We believe Route 92 Medical is positioned for long-term growth with robust manufacturing capacity, a clearly defined market, and a well-differentiated product portfolio,” said Michael Sjöström, CFA, Co-Founder and Partner of Sectoral Asset Management. “Our investment aims to accelerate its commercial growth, helping the company reach many more hospitals and patients.”